Merck buys UK biotech Eyebiotech for up to $3B, acquiring experimental antibody Restoret.
Merck has agreed to buy UK biotech firm Eyebiotech for up to $3 billion, as the company prepares for price pressure on its top-selling cancer therapy, Keytruda, in the coming years. The deal includes an upfront payment of $1.3 billion and potential additional payments of up to $1.7 billion if the company meets future business goals. Eyebiotech's main asset is Restoret, an experimental antibody being developed to treat diseases such as neovascular age-related macular degeneration and diabetic eye disease.
May 29, 2024
20 Articles